A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis (SIRIUS)

Bayer

Status and phase: Enrolling; Phase 2

Conditions: Symptomatic Proximal Deep Vein Thrombosis; Thrombolysis

Treatments: Drug: Placebo to BAY3018250; Drug: BAY3018250

Study type: Interventional

Funder types: Industry

Identifiers

NCT06149520

22138

2023-503315-15-00 (Registry Identifier)

Details and patient eligibility

About

Researchers are looking for a better way to treat people who have deep vein thrombosis (DVT).

DVT is a condition that occurs when a blood clot forms in a deep vein in the leg. DVT is called 'proximal' when the clot is formed in the veins of the hip, thigh, and knee. DVT can cause serious health problems. The blood clots in the veins can break loose and can then travel through the bloodstream and get stuck in the lungs, blocking blood flow to the lungs. Symptoms of DVT include swelling, pain, and tenderness in the affected leg, as well as redness and warmth in the area. Currently, DVT is usually treated using blood thinners to prevent the clot from getting bigger or breaking off and traveling to the lungs. However, blood thinners may not be able to remove a blood clot quickly and may not be suitable for everyone who has DVT.

BAY3018250 is a drug that works by dissolving blood clots. In this study, researchers will compare BAY3018250 with placebo to learn how well it works and how safe it is in participants with proximal DVT. A placebo looks like the study drug but does not have any medicine in it. Using a placebo helps researchers to confirm that the results observed during the study were caused by the study drug and not by other factors.

The main purposes of this study are to learn:

• How well BAY3018250 works in dissolving blood clots in participants with proximal DVT and
• How safe is BAY3018250 as a treatment for participants with proximal DVT?

For this, the researchers will use ultrasound tests to measure blood clots in participants before and at various times after study treatment. They call these measurements a clot burden score. They will compare the clot burden score before and after treatment and will calculate a complex measure called AUC. This tells researchers how the clots have changed over time.

And researchers will collect the number of bleeding events that require medical attention.

The study participants will be randomly (by chance) assigned to one of 3 treatment groups. Dependent on the group, they will receive a single dose of high dose or low dose of BAY3018250 or placebo.

Researchers will closely monitor participants for 90 days after receiving the study treatment.

During the study, the doctors and their study team will:

• take blood samples
• do physical examinations
• examine heart health using electrocardiogram (ECG)
• check vital signs such as blood pressure, heart rate
• undergo ultrasound tests to measure the blood clots
• ask the participants questions about how they are feeling and what adverse events they are having.

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.

Enrollment: 255 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female (if postmenopausal or hysterectomized) aged 18 years or older

• Acute symptomatic proximal deep vein thrombosis (DVT) documented by compression ultrasound (CUS) and all of the following:

  • duration of symptoms 14 days or less
  • Proximal DVT involving at least 1 of the following proximal veins: the popliteal vein, the femoral vein, the common femoral vein and the external iliac vein
  • adequate visualization of the most proximal end of the thrombus
  • receiving therapeutic dose anticoagulation with low molecular weight heparins (LMWHs) and/or direct oral anticoagulants (DOACs) according to the respective product labels

• Measured body weight within 50 to 130 kg

• Signed informed consent

Exclusion criteria

• Acute symptomatic pulmonary embolism (PE) requiring systemic or catheter-directed thrombolytic therapy, catheter-directed mechanical thrombectomy, or surgical embolectomy

• Active bleeding or high risk for bleeding (at the discretion of the investigator)

• Recent (<3 months) ischemic stroke, myocardial infarction, intracranial hemorrhage, or major surgery or severe trauma (at the discretion of the investigator)

• Active cancer, i.e., locally active, regionally invasive or metastatic and/or anticancer therapy within the last 6 months, except basal cell or squamous cell carcinoma

• Therapeutic-dose anticoagulants for > 72 hours before randomization, or current use of vitamin K antagonists

• Planned or current use of the following medications:

  • Any antiplatelet therapy, except acetylsalicylic acid (ASA) ≤100 mg/day
  • Antifibrinolytic drugs
  • Therapeutic antibodies

• Male participants with women of childbearing potential (WOCBP) partners unwilling to use highly effective contraception from start of study intervention until end of study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

255 participants in 3 patient groups, including a placebo group

BAY3018250 Dose 1

Experimental group

Description:

Participants will receive BAY3018250 Dose 1.

Treatment:

Drug: BAY3018250

BAY3018250 Dose 2

Experimental group

Description:

Participants will receive BAY3018250 Dose 2.

Treatment:

Drug: BAY3018250

Placebo to BAY3018250

Placebo Comparator group

Description:

Participants will receive placebo to BAY3018250.

Treatment:

Drug: Placebo to BAY3018250